HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL)

HC Wainwright restated their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research note published on Tuesday morning,Benzinga reports. They currently have a $15.00 price target on the stock.

Werewolf Therapeutics Trading Up 6.7 %

HOWL stock opened at $1.90 on Tuesday. The business has a fifty day moving average of $2.22 and a 200-day moving average of $2.73. Werewolf Therapeutics has a twelve month low of $1.58 and a twelve month high of $8.19. The company has a market cap of $84.66 million, a P/E ratio of -1.24 and a beta of 0.41. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its position in shares of Werewolf Therapeutics by 96.4% in the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after buying an additional 544,881 shares in the last quarter. Janus Henderson Group PLC bought a new stake in shares of Werewolf Therapeutics during the first quarter worth approximately $10,922,000. Acadian Asset Management LLC raised its stake in Werewolf Therapeutics by 119.8% in the 1st quarter. Acadian Asset Management LLC now owns 172,883 shares of the company’s stock worth $1,119,000 after purchasing an additional 94,212 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Werewolf Therapeutics by 26.8% during the 1st quarter. Vanguard Group Inc. now owns 1,107,347 shares of the company’s stock worth $7,176,000 after purchasing an additional 233,909 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Werewolf Therapeutics by 103.1% during the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after acquiring an additional 86,800 shares in the last quarter. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.